Sodium-glucose co-transporter inhibitors

Australian Prescriber

Volumn 37, Issue 1, 2014, Pages 17-20

  Davis, Timothy ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Canagliflozin; Dapagliflozin; Diabetes mellitus type 2; Urinary tract infection

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; GLYCOSYLATED HEMOGLOBIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SODIUM GLUCOSE COTRANSPORTER INHIBITOR; UNCLASSIFIED DRUG;

ADD ON THERAPY; ARTICLE; BLOOD PRESSURE; CALCIUM EXCRETION; CEREBROVASCULAR ACCIDENT; DRUG SAFETY; DRUG WITHDRAWAL; GENITAL TRACT INFECTION; GLOMERULUS FILTRATION RATE; GLUCOSURIA; GLYCEMIC CONTROL; HUMAN; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIA; KIDNEY FAILURE; MILD HEPATIC IMPAIRMENT; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); UROGENITAL TRACT INFECTION; WEIGHT REDUCTION;

EID: 84893277996     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.2014.006     Document Type: Article

References (10)

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:577-96.
2. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011;91:733-94.
3. Australian Government Department of Health and Ageing. Therapeutic Goods Administration. Australian Public Assessment Report for Dapagliflozin propanediol monohydrate. 2013. www.tga.gov.au/pdf/auspar/auspar-dapagliflozin-propanediol-monohydrate-130114.pdf [cited 2013 Nov 14]
4. McIntosh B, Cameron C, Singh SR, Yu C, Ahuja T, Welton NJ, et al. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med 2011;5:e35-48.
5. Bolinder J, Ljunggren O, Johansson L, Wilding J, Langkilde AM, Sjöström CD, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. Epub ahead of print 2013 Aug 1.
6. FDA Briefing Document. NDA 204042. Invokana (canagliflozin) Tablets. Applicant: Janssen Pharmaceuticals, Inc. 2013 Jan. www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/ UCM334550.pdf [cited 2013 Nov 14]
7. Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013;15:463-73.
8. Burki TK. FDA rejects novel diabetes drug over safety fears. Lancet 2012;379:507.
9. Food and Drug Adminstration. FDA approves Invokana to treat type 2 diabetes [news release]. 2013 Mar 29. www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm345848.htm [cited 2013 Nov 19]
10. Thynne T, Doogue M. Experimental and clinical pharmacology. Sodium-glucose co-transporter inhibitors-mechanisms of action. Aust Prescr 2014;37:14-6.